These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3627045)

  • 1. Aluminium load in patients with analgesic nephropathy.
    Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
    Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics of terminal analgesics-induced nephropathy].
    Schwarz A; Pommer W; Kühn-Freitag G; Keller F; Molzahn M; Offermann G
    Schweiz Med Wochenschr; 1985 Jun; 115(23):790-5. PubMed ID: 3875149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone disease in analgesic nephropathy.
    Fassett RG; Lien JW; McClure J; Mathew TH
    Clin Nephrol; 1982 Dec; 18(6):273-9. PubMed ID: 7151345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring.
    Fenwick S; Roberts EA; Mahesh BS; Roberts NB
    Ann Clin Biochem; 2005 Mar; 42(Pt 2):149-52. PubMed ID: 15829127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Particularly severe calcium metabolic disorder in nephropathy from analgesic abuse].
    Jaeger P; Burckhardt P; Wauters JP; Trechsel U; Bonjour JP
    Schweiz Med Wochenschr; 1982 Dec; 112(49):1791-4. PubMed ID: 7178876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for aluminium accumulation in renal failure.
    Marsden SN; Parkinson IS; Ward MK; Ellis HA; Kerr DN
    Proc Eur Dial Transplant Assoc; 1979; 16():588-96. PubMed ID: 549003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aluminum-balance during haemodialysis (author's transl)].
    Graf H; Stummvoll HK; Kovarik J; Meisinger V; Wolf A; Pinggera WF
    Wien Klin Wochenschr; 1980; 92(11):391-4. PubMed ID: 7424016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency].
    Sárszegi Z; Jobst K; Nagy J
    Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperparathyroidism secondary to renal insufficiency: anatomo-clinical relations and the potential role of an aluminum overload].
    Mendes V; Jorgetti V; Nemeth J; Lavergne A; Lecharpentier Y; Cournot-Witmer G; Dubost C; Bourdon R; Bourdeau A; Zingraff J
    Nephrologie; 1984; 5(2):65-70. PubMed ID: 6483074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and clinical course of hemodialysis patients with analgesic-associated nephropathy.
    Schwarz A; Keller F; Kunzendorf U; Kühn-Freitag G; Heinemeyer G; Pommer W; Offermann G
    Clin Nephrol; 1988 Jun; 29(6):299-306. PubMed ID: 3396233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)].
    Boukari M; Rottembourg J; Jaudon MC; Clavel JP; Legrain M; Galli A
    Nouv Presse Med; 1978 Jan; 7(2):85-8. PubMed ID: 349501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity of patients with analgesic-associated nephropathy and end-stage renal failure.
    Schwarz A; Pommer W; Keller F; Kuehn-Freitag G; Offermann G; Molzahn M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():311-6. PubMed ID: 3991517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.